Droperidol QT risk management
Executive Summary
Risk management and assessment for QTc prolongation associated with the anesthetic/antiemetic droperidol (Akorn's Inapsine and generics) will be discussed by FDA's Anesthetic & Life Support Drugs Advisory Committee on Nov. 18. Several risk management steps were implemented when the safety concern was discovered in December 2001 (1"The Pink Sheet" Dec. 10, 2001, p. 23). The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m. [To 2watch a webcast or video of this and other meetings, go to FDAAdvisoryCommittee.com.]....